The two sector before the end of October will be the national drug reimbursement list included in th cm68.com

The two sector: before the end of October will be the national drug reimbursement list included in the new rural cooperative negotiation – Fujian Channel – people.com.cn original title: two departments: before the end of October will be the national drug reimbursement list included in the new rural cooperative negotiation according to the national health and Family Planning Commission website news, the national health and Family Planning Commission Office, general office of the Ministry of Finance recently issued a notice requirement do the national drug negotiations with the new rural cooperative medical reimbursement policy convergence. "Notice" clearly, the provinces have not yet adjusted, should be combined with local conditions, based on the implementation of price negotiations, and strive to be the national bargaining drugs into the NCMS reimbursement drug list before the end of October 2016. National Health and Family Planning Commission announced the first batch of national drug price negotiations results 5 month 20 day, including chronic hepatitis B drug tenofovir first-line treatment of non-small cell lung cancer, targeted therapy of icotinib and gefitinib. Compared with the purchase price of public hospitals, the price of 3 kinds of negotiation drugs decreased by more than 50%. According to the circular, the establishment of the national drug price negotiation mechanism is an innovative measure to deepen the reform of the medical and health system, improve the drug procurement mechanism, reduce the burden of drug use of the majority of patients, and enhance the people’s recognition and sense of gain. It is of great significance to make the national negotiation drug and the new rural cooperative medical reimbursement policy convergence, so that the people benefit in time. "Notice" stressed that according to the national drug price negotiations results, timely adjustment of NCMS reimbursement list of drugs. The provinces have not yet adjusted, according to the local economic development, the level of the NCMS funding, the ability of medical services, where the change of disease spectrum and the actual situation, based on the implementation of negotiations, and strive to 2016 years 10 before the end of the national bargaining drugs into the NCMS reimbursement drug list, and report to the national health and Family Planning Commission grassroots division for the record. In the areas where the expenditure of funds is high, some varieties can be selected or started from serious illness insurance. "Notice" requirements, and effectively improve the accessibility and affordability of patients. In accordance with the relevant requirements, the government should do a good job in the procurement, distribution, use and reimbursement of drugs for national negotiation, thus forming a policy resultant force. In the process of balancing the basic medical insurance for urban and rural residents and the unified reimbursement policy, the negotiation drugs should be brought into the scope of reimbursement. At the same time, do a good job of monitoring and evaluation, strengthen publicity and guidance, and actively respond to social concerns, guide reasonable expectations, create a good atmosphere. Annex: in 2015, the national drug price negotiation results are as follows: 1. the negotiation price is the purchase price of public medical institutions based on the current medical insurance policy (including the distribution cost); 2., the procurement cycle is 2016 ~ 2017. (commissioning editor Wu Zhou and Zhang Zijian)

两部门:10月底前将国家谈判药品纳入新农合报销目录–福建频道–人民网 原标题:两部门:10月底前将国家谈判药品纳入新农合报销目录   据国家卫生和计划生育委员会网站消息,国家卫生计生委办公厅、财政部办公厅近日印发通知,要求做好国家谈判药品与新型农村合作医疗报销政策衔接。《通知》明确,尚未调整的省份,要结合当地实际情况,在执行谈判价格的基础上,力争在2016年10月底前将国家谈判药品纳入新农合报销药物目录。   国家卫生计生委5月20日公布首批国家药品价格谈判结果,其中有慢性乙肝一线治疗药物替诺福韦酯,非小细胞肺癌靶向治疗药物埃克替尼和吉非替尼。与之前公立医院的采购价格比较,3种谈判药品价格降幅均在50%以上。   《通知》称,建立国家药品价格谈判机制是深化医药卫生体制改革、完善药品采购机制、降低广大患者用药负担、增强人民群众认同感和获得感的创新举措。做好国家谈判药品与新型农村合作医疗报销政策衔接,使老百姓及时受益,意义重大。   《通知》强调,根据国家药品价格谈判结果及时调整新农合报销药物目录。尚未调整的省份,要结合当地经济发展、新农合筹资水平、医疗服务能力、地方疾病谱变化等实际情况,在执行谈判价格的基础上,力争在2016年10月底前将国家谈判药品纳入新农合报销药物目录,并报国家卫生计生委基层司备案。基金支出压力较大的地区,可选择部分品种或从大病保险做起。   《通知》要求,切实提高患者用药的可及性和可负担性。各地要按照有关要求认真做好国家谈判药品的采购、配送、使用和报销等各项工作,形成政策合力。在统筹城乡居民基本医疗保险、统一报销政策的过程中,及时将谈判药品纳入报销范围。同时,做好监测评估,加强宣传引导,积极回应社会关切,引导合理预期,营造良好氛围。   附件:   2015年国家药品价格谈判结果   备注:1.谈判价格为基于与现行医保政策相衔接的公立医疗机构采购价格(含配送费用);   2.采购周期为2016�2017年。 (责编:吴舟、张子剑)相关的主题文章: